Progress on the BRD4 of super enhancer regulatory element in hematologic oncology
10.3760/cma.j.issn.1673-4408.2022.04.006
- VernacularTitle:超级增强子调控点BRD4在血液肿瘤中的研究进展
- Author:
Shuiyan WU
1
;
Qi JI
;
Shaoyan HU
Author Information
1. 苏州大学附属儿童医院血液肿瘤科 215000
- Keywords:
Super enhancers;
Bromodomain protein 4;
Hematologic oncology;
Molecular medicine
- From:
International Journal of Pediatrics
2022;49(4):241-244
- CountryChina
- Language:Chinese
-
Abstract:
Abnormal transcription of oncogenes driven by super enhancers was found to be critical for maintaining tumor cell identity.The expression of oncogenes can be effectively suppressed by inhibiting the key regulator that super enhancers regulate oncogene transcription.Bromodomain protein 4(BRD4)is a key protein to recognize the super enhancer regulatory elements, which can bind to acetylated histones or non-histones to regulate gene transcription.The abnormal expression of BRD4 is closely related to the malignant development of a variety of hematologic oncology.Targeting BRD4 can effectively control the malignant development of hematologic tumors.In recent years, BRD4-targeted drugs in hematologic oncology have received extensive attention, and they showed good antitumor effects either as a single drug or in combination with other drugs.In this paper, in order to provide a new understanding of the occurrence of leukemia and treatment of hematologic oncology, the biological functions of BRD4 as well as the molecular drugs targeting BRD4 are reviewed.
